![Sample our Bioscience journals, sign in here to start your access, Latest two full volumes FREE to you for 14 days]({"type":"image" , "src" : "/sda/5925/TOC-Subject-Sample-2021-Bioscience.jpg"})
ABSTRACT
Introduction: Levodopa induced dyskinesia (LID) is a common motor complication affecting almost 95% of patients after 15 years of levodopa therapy. Dyskinesia in Parkinson`s disease (PD) can be functionally and socially disabling. Amantadine ER/ADS-5102/Gocovri™ is the first and only drug to get FDA approval in August 2017 for treatment of dyskinesias in patients with PD receiving levodopa with or without concomitant dopaminergic medication.
Areas covered: This review summarizes the pharmacodynamics, safety and efficacy of Amantadine ER/ADS 5102 in the treatment of LID.
Expert opinion: LID is a challenging problem in Parkinson’s disease. Although Amantadine IR is effective in treating LID, it is associated with a higher risk of CNS related side effects including sleep disturbances. Pharmacokinetic profile of Amantadine ER formulation consists of a slow rise and a sustained plasma level of approximately twice the level achieved by amantadine IR formulation. Once nighttime dosing of Amantadine ER provides a slow increase in plasma levels during the night and achieves the goal of maximal serum level during the most active hours of morning and mid-day making amantadine ER better tolerated and more efficacious as compared to IR formulations, in PD patients with troublesome dyskinesias.
Declaration of interest
P Agarwal receives research funding from ADAMAS pharmaceuticals and is a consultant and speaker for ADAMAS pharmaceuticals. The authors have no other relevant affiliations or financial involvement with any organization or entity with a financial interest in or financial conflict with the subject matter or materials discussed in the manuscript apart from those disclosed.
Reviewer Disclosures
Peer reviewers on this manuscript have no relevant financial relationships or otherwise to disclose.